
Volitionrx Limited (VNRX) Stock Forecast & Price Target
Volitionrx Limited (VNRX) Analyst Ratings
Bulls say
VolitionRX Ltd is well-positioned for growth in the pharmaco-epigenetics space, bolstered by ongoing collaborations and partnerships that could enhance revenue and adoption of its biomarker technology. The significant validation of the Nu.Q Lung Cancer Test, along with discussions with major diagnostic and pharmaceutical companies, indicates a trajectory toward successful strategic partnerships, which would de-risk the company’s technological investments. Additionally, the successful adoption of its Nu.Q Discover biomarkers in over 1,000 veterinary hospitals in Japan points to strong market interest and potential for increased revenue, particularly with the imminent transition to an automated system.
Bears say
VolitionRX Ltd is attempting to address significant challenges related to high false-positive rates in low-dose computed tomography (LDCT) screenings, which may hinder its ability to gain traction in the diagnostic market despite its innovative Nucleosomics platform. The high rate of unnecessary invasive procedures associated with the company's testing approach could adversely affect its reputation and adoption among healthcare providers, potentially impacting future revenue growth. Additionally, the focus on human diagnostics alongside animal diagnostics may dilute the company’s resources and strategic focus, creating further uncertainties around its financial performance and marketability.
This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.
Volitionrx Limited (VNRX) Analyst Forecast & Price Prediction
Start investing in Volitionrx Limited (VNRX)
Order type
Buy in
Order amount
Est. shares
0 shares